Bioelectronics Corp (BIEL)

[ddls]

The company can't make money on $5-trial ActiPatches.

More ActiDilution coming up!

And the FDA will Acti-NSE this again.

"The Company was granted its first approval from the FDA under a 510(k) in August 2002. Prior to FDA approval
and the establishment of its research and development group, PAW, LLC (an entity owned by the family of
Andrew Whelan, President) funded the operations and costs of product development. The Company has submitted
a new market clearance application on August 7, 2015 that includes three clinical studies, two in chronic and one
acute musculoskeletal pain. The consumer data from 5,000+ users with an average baseline Visual Analogue
Scale (VAS) score of 8.1 (scale is 0-10) demonstrated a signicant reduction in chronic pain."

"The Company has reduced the clinic
apparatus to wafer thin disposable devices that are applied directly to the body. The extended duration dual
therapy of heat and electric restoration is significantly safer and more effective than competitive heat or cold pads
and pain medications. The devices consist of an inexpensive microchip, battery and antenna that deliver the
therapy more effectively." FDA-ActiNSE

"The Company has entered into convertible promissory note agreements with various other related parties of the
Company. Other related parties consist of family members of the President of the Company. Additionally, St.
Johns, LLC is a limited liability company, which is owned by a family member of the President of the Company.
Other related parties consist of Robert Whelan and Janel Zaluski, the son and daughter of the President, Mary
Whelan, the sister of the President, St. John’s LLC, which is owned by family members of the President, and
Richard Staelin, who is Chairman of the Board of Directors.
Each of the promissory notes bears simple interest at 8% per annum, and all accrued interest and principal is due

LMAO What a ActiJoke!